Post-pandemic healthcare trends will turn, says SEB's new biotech portfolio lead

The life science industry has "pent-up demand" and could see a reversal in some segments' performances as the post-pandemic world starts to normalize, according to Sweden's SEB Investment Management, which has just switched approach to its healthcare and biotech funds after these were surpassed by their benchmarks. The new strategy seeks to better utilize investment opportunities within the sector.
Photo: Photo: Pexels: Martin Lopez.
Photo: Photo: Pexels: Martin Lopez.

Some of the prevailing trends in healthcare and biotech funds during the Covid-19 pandemic will reverse as the economy opens up post-pandemic, says Angelica Fatouros, portfolio manager of healthcare and biotechnology funds at SEB Investment Management.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading